Dr. Nicole Schneiderhan-Marra

Arbeitsgebiete

- Entwicklung, Validierung und Anwendung von Antigenarrays und multiplexen serologischen Immunoassays zur Pathogen Infektionsdiagnostik
 
- Entwicklung, Validierung und Anwendung miniaturisierter multiplexer Sandwich Immunoassays in der Proteomforschung für pharmazeutische und klinische Fragestellungen.

Werdegang mit den wichtigsten Stationen
 
seit 11/2019  stellvertretende Bereichsleiterin Pharma und Biotech
 
seit 01/2018  Abteilungsleiterin Biochemie

06/2007 – 12/2017  Stellvertretende Abteilungsleiterin Biochemie

seit 05/2005  Projektleiterin und Laborleitung am NMI Reutlingen

2003 - 2005  Wissenschaftliche Angestellte an der Universität Ulm, Universitätsfrauenklinik, Endokrinologisches und Onkologisches Labor, Arbeitsgruppe Prof. Helmut Deißler

2002  Externe Promotionsarbeit (Dr. rer. nat.)  an der Universität Tübingen und Medizinische Klinik IV, Nephrologische Forschungslaboratiorien, Friedrich-Alexander-Universität Erlangen-Nürnberg.
Titel: Molekularer Mechanismus der Stickstoffmonoxid-vermittelten Akkumulation des Tumorsuppressors p53

09 -10/2011  Stipendium der Boehringer Ingelheim Fonds für einen Forschungsaufenthalt am “MD Anderson Cancer Center“, Houston, Texas, USA

1992 - 1998  Studium der Biochemie an der Eberhard-Karls-Universität Tübingen

Dr. Nicole Schneiderhan-Marra

Gruppenleiterin Biochemie
Diplom-Biochemikerin
T +49 (0)7121 51530-815
F +49 (0)7121 51530-16

Publikationen

  • A mass spectrometry guided approach for the identification of novel vaccine candidates in gramnegative pathogens
    Hornburg D, Kruse T, Anderl F, Daschkin C, Semper R P, Klar K, Guenther A, Mejías-Luque R, Schneiderhan-Marra N, Mann M, Meissner F & Gerhard M
    Sci Rep 9, 17401 (2019) https://doi.org/10.1038/s41598-019-53493-8
  • A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer
    Rammensee H-G, Wiesmüller K-H, Chandran P A, Zelab H, Rusch E, Gouttefangea C, Kowalewski D J, Di Marco M, Hean S P, Walz J S, Gloria Y C, Bödder J, Schertel J-M, Tunger A, Müller L, Kießler M, Wehner R, Schmitz M, Jakobi M, Schneiderhan-Marra N, Klein R, Laske K, Artzner K, Backert L, Schuster H, Schwenck J, Weber A N R, Pichler B J, Kneilling M, la Fougère C, Forchhammer S, Metzler G, Bauer J, Weide B, Schippert W, Stevanovic S u. Löffler M W
    Journal for ImmunoTherapy of Cancer (2019) 7:307 https://doi.org/10.1186/s40425-019-0796-5
  • Serum inflammatory profile for the discrimination of clinical subtypes in Parkinson’s disease
    Yilmaz R, Strafella A, Bernard A, Schulte C, van den Huevel L, Schneiderhan-Marra N, Knorpp T, Joos T, Leypoldt F, Geritz J, Hansen C, Apel A, Gasser T, Lang A, Berg D, Maetzler W, Marras C
    Front Neurol., 2018 Dec 21 DOI:/10.3389/fneur.2018.01123
  • Low-picomolar, label-free procalcitonin analytical detection with an electrolyte-gated organic field-effect transistor based electronic immunosensor. Biosens Bioelectron
    Seshadri P, Manoli K, Schneiderhan-Marra N, Anthes U, Wierzchowiec P, Bonrad K, Di Franco C, Torsi L.
    Biosens Bioelectron. 2018 May 1;104:113-119. doi: 10.1016/j.bios.2017.12.041. Epub 2017 Dec 26.
  • Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology
    Bohm K, Filomena A, Schneiderhan-Marra N, Krause G, Sievers C
    Vaccine. 2017 Oct 13;35(43):5883-5889. doi: 10.1016/j.vaccine.2017.08.089. Epub 2017 Sep 14.
  • Performance of a Multiplex Serological Helicobacter pylori Assay on a Novel Microfluidic Assay Platform
    Filomena A, Guenther A, Planatscher H, Topin F, She J, Formichella L, Terradot L, Gerhard M, Joos TO, Meyer H, Schneiderhan-Marra N
    Proteomes. 2017 Oct 3;5(4). pii: E24. doi: 10.3390/proteomes5040024.
  • Study of the Humoral Immune Response towards HCV Genotype 4 Using a Bead-Based Multiplex Serological Assay
    Filomena A, Göpfert JC, Duffy D, Pol S, Abdel-Hamid M, Esmat G, Fontanet A, Albert M, Joos T, Schneiderhan-Marra N
    High-Throughput. 2017; 6(4): 15.
  • Development of a Bead-Based Multiplex Assay for the Analysis of the Serological Response against the Six Pathogens HAV, HBV, HCV, CMV, T. gondii, and H. pylori
    Filomena A, Pessler F, Akmatov M, Krause G, Duffy D, Gärtner B, Gerhard M, Albert M, Joos T, Schneiderhan-Marra N,
    High-Throughput. 2017; 6(4): 14.
  • Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's disease
    Brockmann K, Schulte C, Schneiderhan-Marra N, Apel A, Pont-Sunyer C, Vilas D, Ruiz-Martinez J, Langkamp M, Corvol JC, Cormier F, Knorpp T, Joos TO, Bernard A, Gasser T, Marras C, Schule B, Aasly JO, Foroud T, Marti-Masso JF, Brice A, Tolosa E, Berg D, Maetzler W
    Eur J Neurol. 2017 Feb;24(2):427-e6. doi: 10.1111/ene.13223.
  • A standardized production pipeline for high profile targets from Mycobacterium tuberculosis
    Milewski MC, Broger T, Kirkpatrick J, Filomena A, Komadina D, Schneiderhan-Marra N, Wilmanns M, Parret AH
    Proteomics Clin Appl. 2016 Oct;10(9-10):1049-1057. doi: 10.1002/prca.201600033. Epub 2016 Aug 3.
  • Personalized peptide vaccine induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient
    Loffler MW, Anoop Chandran P, Laske K, Schroeder C, Bonzheimm I, Walzer M, Hilke FJ, Trautwein N, Kowalewski DJ, Schuster H, Gunder M, Carcamo Yanez VA, Mohr C, Sturm M, Nguyen HP, Riess O, Bauer P, Nahnsen S, Nadalin S, Zieker D, Glatzle J, Thiel K, Schneiderhan-Marra N, Clasen S, Bosmuller H, Fend F, Kohlbacher O, Gouttefangeas C, Stevanovic S, Konigsrainer A, Rammensee HG
    J Hepatol. 2016 Oct;65(4):849-855. doi: 10.1016/j.jhep.2016.06.027. Epub 2016 Jul 7.
  • Inflammatory profile in LRRK2-associated prodromal and clinical PD
    Brockmann K, Apel A, Schulte C, Schneiderhan-Marra N, Pont-Sunyer C, Vilas D, Ruiz-Martinez J, Langkamp M, Corvol JC, Cormier F, Knorpp T, Joos TO, Gasser T, Schule B, Aasly JO, Foroud T, Marti-Masso JF, Brice A, Tolosa E, Marras C, Berg D, Maetzler W
    J Neuroinflammation. 2016 May 24;13(1):122. doi: 10.1186/s12974-016-0588-5.
  • Pre-Analytical Parameters Affecting Vascular Endothelial Growth Factor Measurement in Plasma: Identifying Confounders
    Walz JM, Boehringer D, Deissler HL, Faerber L, Goepfert JC, Heiduschka P, Kleeberger SM, Klettner A, Krohne TU, Schneiderhan-Marra N, Ziemssen F, Stahl A
    PLoS One. 2016 Jan 5;11(1):e0145375. doi: 10.1371/journal.pone.0145375. eCollection 2016.
  • Bead-Based Peptide Arrays for Profiling the Specificity of Modification State-Specific Antibodies
    Filomena A, Beiter Y, Templin MF, Joos TO, Schneiderhan-Marra N, Poetz O
    Methods Mol Biol. 2015;1348:251-65. doi: 10.1007/978-1-4939-2999-3_22.
  • Characterization of immunologically active drugs in a novel organotypic co-culture model of the human gut and whole blood
    Schmohl M, Schneiderhan-Marra N, Baur N, Hefner K, Blum M, Stein GM, Joos TO, Schmolz M
    Int Immunopharmacol. 2012 Oct 24;14(4):722-728. doi: 10.1016/j.intimp.2012.10.010.
  • Receptor tyrosine kinase inhibitor profiling using bead-based multiplex sandwich immunoassays
    Poetz O, Schneiderhan-Marra N, Henzler T, Herget T, Joos TO
    Methods Mol Biol. 2012;795:191-202. doi: 10.1007/978-1-61779-337-0_13.
  • A generic operational strategy to qualify translational safety biomarkers
    Matheis K, Laurie D, Andriamandroso C, Arber N, Badimon L, Benain X, Bendjama K, Clavier I, Colman P, Firat H, Goepfert J, Hall S, Joos T, Kraus S, Kretschmer A, Merz M, Planatscher H, Schneiderhan-Marra N
    Drug Discov Today. 2011 July; 16(13-14): 600-608. DOI 10.1016/j.drudis.2011.04.011
  • Molecular indicators of non-sentinel node status in breast cancer determined in preoperative biopsies by multiplexed sandwich immunoassays
    Sauer G, Schneiderhan-Marra N, Muche R, Koretz K, Kazmaier C, Kreienberg R, Joos T, Deissler H
    J Cancer Res Clin Oncol. 2011 Aug;137(8):1175-84. Epub 2011 Apr 24.
  • Triple-negative breast cancer: present challenges and new perspectives
    Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, Postma GJ, Schneiderhan-Marra N, Santoro F, Wouters H, Russnes HG, Sorlie T et al.
    Mol Oncol. 2010 Jun;4(3):209-29. Epub 2010 Apr 24. doi: 10.1016/j.molonc.2010.04.006
  • Multiplexed immunoassays for the analysis of breast cancer biopsies
    Schneiderhan-Marra N, Sauer G, Kazmaier C, Hsu HY, Koretz K, Deissler H, Joos TO
    Anal Bioanal Chem. 2010 Aug;397(8):3329-38. doi: 10.1007/s00216-010-3873-7. Epub 2010 Jul 18.
  • Protein microarrays for personalized medicine
    Yu X, Schneiderhan-Marra N, Joos TO
    Clin Chem. 2010 Mar;56(3):376-87. Epub 2010 Jan 14. doi: 10.1373/clinchem.2009.137158
  • Protein-protein-interactions in a multiplexed, miniaturized format a functional analysis of Rho GTPase activation and inhibition
    Schmohl M, Rimmele S, Potz O, Kloog Y, Gierschik P, Joos TO, Schneiderhan-Marra N
    Proteomics. 2010 Apr;10(8):1716-20. doi: 10.1002/pmic.200900597.
  • Bead-based protein-protein interaction assays for the analysis of Rho GTPase signaling
    Rimmele S, Gierschik P, Joos TO, Schneiderhan-Marra N
    J Mol Recognit. 2010 Nov-Dec;23(6):543-50. doi: 10.1002/jmr.1051.
  • Prediction of Nodal Involvement in Breast Cancer Based on Multiparametric Protein Analyses from Preoperative Core Needle Biopsies of the Primary Lesion.
    Sauer G, Schneiderhan-Marra N, Kazmaier C, Hutzel K, Koretz K, Muche R, Kreienberg R, Joos T, Deissler H
    Clin Cancer Res. 2008 Jun 1;14(11):3345-3353. doi: 10.1158/1078-0432.CCR-07-4802.
  • A Cryptic Vascular Endothelial Growth Factor T-Cell Epitope: Identification and Characterization by Mass Spectrometry and T-Cell Assays
    Weinzierl AO, Maurer D, Altenberend F, Schneiderhan-Marra N, Klingel K, Schoor O, Wernet D, Joos T, Rammensee HG, Stevanovic S (2008)
    Cancer Res. 2008 Apr 1;68(7):2447-54. doi: 10.1158/0008-5472.CAN-07-2540
  • Protein Microarrays - A Promising Tool for Cancer Diagnosis
    Schneiderhan-Marra N, Kirn A, Döttinger A, Templin M, Sauer G, Deissler H, Joos TO
    Cancer Genomics & Proteomics. 2005 Jan; 2(1): 37-42.
  • Retinoblastoma susceptibility gene product pRB activates hypoxia-inducible factor-1 (HIF-1)
    Budde A, Schneiderhan-Marra N, Petersen G, Brune B
    Oncogene. 2005; 24(10): 1802-8. DOI: 10.1038/sj.onc.1208369